Details Basic Details Approval Date Thursday, September 12, 2019 Health Outcome(s) inflammatory bowel disease (IBD) Regulatory Link(s) (2) ARIA Memo FDA Approval Package Link(s) Sentinel Drug Study: Ibsrela (Tenapanor) & Inflammatory Bowel Disease (IBD)